The history of the agnostic targeting of neoplastic growth originates from attempts to utilize tamoxifen, a well-known breast cancer drug directed against the estrogen receptor (ER), for the treatment of ER+ pulmonary lymphangiomyomatosis [6]. This evidence concerns the gene ESR1 and lung lymphangioleiomyomatosis.